D. Ford

发表

Lowering whole-body radiation doses in pediatric intensity-modulated radiotherapy through the use of unflattened photon beams.

Jason Cashmore, Mark Ramtohul, Dan Ford, 2011, International journal of radiation oncology, biology, physics.

External beam radiotherapy in the management of differentiated thyroid cancer.

C. McConkey, J. Watkinson, A. Hartley, 2003, Clinical oncology (Royal College of Radiologists (Great Britain)).

Radical treatment of muscle-invasive bladder cancer—are options equal?

A. Zarkar, A. Marshall, J. Dunn, 2018, Journal of Radiation Oncology.

Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer

N. James, A. Zarkar, R. Stevenson, 2022, BJUI compass.

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol

Warren C. Grant, M. Parmar, M. Sydes, 2021, The Lancet.

Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial

M. Sydes, D. Dearnaley, C. Parker, 2022, PLoS medicine.

Primary bone lymphoma--treatment and outcome.

R. Grimer, S. Sothi, D. Spooner, 2007, Clinical oncology (Royal College of Radiologists (Great Britain)).

Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial.

J. Staffurth, V. Hinder, E. Hall, 2022, The Lancet. Oncology.

Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol

M. Parmar, M. Sydes, D. Dearnaley, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA.

J. Carles, Choung-Soo Kim, A. Font, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Management of newly diagnosed metastatic hormone‐sensitive prostate cancer: A survey of UK Uro‐oncologists

H. Payne, Robert J. Jones, S. Crabb, 2020, International journal of clinical practice.

Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial

G. Rodrigues, J. Staffurth, T. Tsakiridis, 2019, The Lancet. Oncology.

Mapping FACT-P to EQ-5D in a large cross-sectional study of metastatic castration-resistant prostate cancer patients

P. Hamberg, J. Diels, D. Ford, 2014, Quality of Life Research.

Evaluation of the added value of 1H-magnetic resonance spectroscopy for the diagnosis of pediatric brain lesions in clinical practice

Karen A Manias, Martin Wilson, A. Peet, 2017, Neuro-oncology practice.

TUXEDO: a phase I/II trial of cetuximab with chemoradiotherapy in muscle‐invasive bladder cancer

N. James, A. Zarkar, R. Viney, 2022, BJU international.

The sequential use of abiraterone and enzalutamide (MDV3100) in castrate resistant prostate cancer patients: Experience from Birmingham, United Kingdom.

N. James, E. Porfiri, A. Zarkar, 2013 .

Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747).

C. Parker, L. Billingham, D. McLaren, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The sequential use of abiraterone and enzalutamide in metastatic castrate resistant prostate cancer patients: Experience from seven U.K. centers.

N. James, E. Porfiri, A. Zarkar, 2014 .

Urine DNA for monitoring chemoradiotherapy response in muscle‐invasive bladder cancer: a pilot study

Reid F. Thompson, N. James, D. Ward, 2021, BJU international.

Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476)

M. Parmar, M. Sydes, D. Dearnaley, 2022, International journal of cancer.

Toxicity and Patient-Reported Outcomes of a Phase 2 Randomized Trial of Prostate and Pelvic Lymph Node Versus Prostate only Radiotherapy in Advanced Localised Prostate Cancer (PIVOTAL)

D. Dearnaley, V. Khoo, J. Staffurth, 2019, International journal of radiation oncology, biology, physics.

Vertebral compression fracture rate following stereotactic ablative body radiotherapy for spine oligometastases: a UK experience

A. Zarkar, J. Sherriff, A. El-Modir, 2021, Journal of Radiotherapy in Practice.

Phase III non-inferiority study of cabazitaxel (C) 20 mg/m2 (C20) versus 25 mg/m2 (C25) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D).

J. Carles, J. Bono, Choung-Soo Kim, 2016 .

The delivery of radical radiotherapy to the bladder and pelvis in node-positive (N1) bladder cancer: a five patient case series

N. James, D. Ford, S. Chetiyawardana, 2016, BJR case reports.

Comparison of two doses of cabazitaxel plus prednisone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel (D)-containing regimen

J. Carles, H. Pandha, J. Bono, 2012 .

PROSELICA: Health-related quality of life (HRQL) and post-hoc analyses for the phase 3 study assessing cabazitaxel 20 (C20) vs 25 (C25) mg/m2 post-docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

J. Carles, J. Bono, Choung-Soo Kim, 2016 .

PACE-A: An international phase 3 randomised controlled trial (RCT) comparing stereotactic body radiotherapy (SBRT) to surgery for localised prostate cancer (LPCa)—Primary endpoint analysis.

A. Thompson, C. Griffin, E. Hall, 2023, Journal of Clinical Oncology.

PACE: Analysis of acute toxicity in PACE-B, an international phase III randomized controlled trial comparing stereotactic body radiotherapy (SBRT) to conventionally fractionated or moderately hypofractionated external beam radiotherapy (CFMHRT) for localized prostate cancer (LPCa).

J. Staffurth, V. Hinder, C. Griffin, 2019, Journal of Clinical Oncology.

OC-0289 Comparison of side effects at 2 years in the randomised PACE-B trial (SBRT vs standard radiotherapy)

J. Staffurth, C. Griffin, W. Chu, 2021, Radiotherapy and Oncology.

PROSELICA study update: Comparison of two doses of cabazitaxel (Cbz) plus prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel (D)-containing regimen.

J. Carles, J. Bono, V. Matveev, 2013 .